ReutersReuters

InflaRx NV reports results for the quarter ended June 30 - Earnings Summary

RefinitivBacaan 1 minit
  • InflaRx NV IFRX reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of seven analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -21 cents to -10 cents per share.

  • Reported revenue was zero​; analysts expected €50.17 thousand.

  • InflaRx NV's reported EPS for the quarter was a loss of 21 cents​.

  • The company reported a quarterly loss of €14.42 million.

  • InflaRx NV shares had risen by 6.3% this quarter and lost 66.0% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had fallen by about 13.6% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

  • Wall Street's median 12-month price target for InflaRx NV is $3.00, about 72% above its last closing price of $0.84

This summary was machine generated from LSEG data August 7 at 05:08 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Jun. 30 2025

-0.18

-0.21

Missed

Mar. 31 2025

-0.18

-0.13

Beat

Dec. 31 2024

-0.25

-0.08

Beat

Sep. 30 2024

-0.25

-0.30

Missed

Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini